GLAXOSMITHKLINE PLC Form 6-K February 21, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 20 February 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

#### GlaxoSmithKline plc

(the Company)

GlaxoSmithKline plc (the 'Company')

Shares withheld or sold to meet tax liabilities

Following the vesting of awards granted in 2014 under the GlaxoSmithKline 2009 Performance Share Plan on 16 February 2017 and as notified on 17 February 2017, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them ('PCA") in Ordinary Shares and in American Depositary Shares (ADSs) of the Company arising from the sale or withholding of Ordinary Shares or ADSs to meet tax liabilities. This notification also includes the sale further to the vesting of awards granted in 2012 to Sir Andrew Witty which were subject to an additional holding period. Transaction notification

1.	Details of PDMR/person closely associa		
a) b)	Name Desition (status	Sir Andrew	utive Officer
D)	Position/status Initial notification/	Chief Exec	utive Officer
c)	amendment	Initial notif	fication
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market par	ticipant, auction
a)	Name	GlaxoSmit	hKline nlc
	LEI		ZTVUYLO1D793
0)	Details of the transaction(s): section to b		
3.	instrument; (ii) each type of transaction;	-	•••
5.	place where transaction(s) has been cond	. ,	
			hares of 25 pence
		•	nary Shares')
a)	Description of the financial instrument	(	<b>,</b>
		ISIN: GB0	009252882
		The sale of	Ordinary Shares
	Nature of the transaction	to meet tax liabilities for the	
1 \		vesting of awards granted in	
D)		2012 and 2014 under the	
		Company's 2009	
		Performance Share Plan.	
		Price(s)	Volume(s)
()	$\mathbf{D}$ mixed (a) and we have $\mathbf{D}$	£16.2437	,
C)	Price(s) and volume(s)	£16.2437	166
		£16.2437	55,441
	Aggregated information		
d)		64,664	£16.2437
	Aggregated volume Price		
e)	Date of the transaction	2017-02-16	
f)	Place of the transaction		ock Exchange
1)		(XLON)	

1.	Details of PDMR/person closely associa	ted with them ('PCA')	
	Name	Ms E Walmsley	
b)	Position/status	CEO Designate	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance	e market participant, auction	
a)	platform, auctioneer or auction monitor Name	GlaxoSmithKline plc	
	LEI	5493000HZTVUYLO1D793	
0)	Details of the transaction(s): section to b		
3.	instrument; (ii) each type of transaction;		
	place where transaction(s) has been cond		
		Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
		ISIN: GB0009252882	
		The sale of Ordinary Shares	
		to meet tax liabilities for the	
h)	Nature of the transaction	vesting of awards granted in	
D)	Nature of the transaction	2014 under the Company's	
		2009 Performance Share	
		Plan.	
c)	Price(s) and volume(s)	Price(s) Volume(s)	
0)		£16.2437 19,218	
d)	Aggregated information	n/a (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2017-02-16	
f)	Place of the transaction	London Stock Exchange	
1)		(XLON)	
1.	Details of PDMR/person closely associa	ted with them ('PCA')	
a)	Name	Mr R G Connor	
<b>b</b> )	Position/status	President, Global	
0)		Manufacturing and Supply	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to b	e repeated for (i) each type of	
3.	instrument; (ii) each type of transaction;		
	place where transaction(s) has been cond		
		Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
	r	10D1 (D0000000000	
<b>ኤ</b> ነ	Natura of the transaction	ISIN: GB0009252882	

		2014 under the Company's 2009 Performance Share Plan.	
c)	Price(s) and volume(s)	Price(s) £16.2437	Volume(s) 14,957
d)	Aggregated information	n/a (single tra	
	Aggregated volume Price		
e)	Date of the transaction	2017-02-16	
f)	Place of the transaction	London Stocl (XLON)	k Exchange
1.	Details of PDMR/person closely associat		
a) b)	Name Position/status	Mr S Dingen Chief Financi	
	Initial notification/		
c)	amendment	Initial notific	ation
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	-	-
	Name	GlaxoSmithK	Kline plc VUYLO1D793
b)	LEI Details of the transaction(s): section to be		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
	place where transaction(s) has been cond		
a)	Description of the financial instrument	Ordinary shar each ('Ordina	res of 25 pence ry Shares')
b)	Nature of the transaction	to meet tax livesting of aw 2014 under th 2009 Perform Plan.	ordinary Shares abilities for the vards granted in ne Company's nance Share
c)	Price(s) and volume(s)	Price(s) £16.2437	Volume(s) 32,529
d)	Aggregated information	n/a (single tra	,
	Aggregated volume Price		
e)	Date of the transaction Place of the transaction	2017-02-16 London Stocl	r Evolopgo
f)		(XLON)	LACHAIIge
1. a)	Details of PDMR/person closely associat Name	ed with them Mr N Hirons SVP, Global	
b)	Position/status	Compliance	Luits &
c)	Initial notification/ amendment	Initial notific	ation
2	Details of the issuer, emission allowance	market partic	ipant, auction

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

	Eugai Filing	J. GLANUSI	
b) 3.	Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	e repeated fo (iii) each dat lucted GlaxoSmith American D	TVUYLO1D793 or (i) each type of te; and (iv) each
a)	Description of the financial instrument	('ADSs')	
b)	Nature of the transaction	meet tax liat the vesting of in 2014 und 2009 Perfor Plan.	lding of ADSs to bilities further to of awards granted er the Company's mance Share
c)	Price(s) and volume(s)	Price(s) \$40.57	Volume(s) 1,255
	Aggregated information	n/a (single t	
d)		<b>6</b>	,
- )	Aggregated volume Price	2017 02 16	
	Date of the transaction Place of the transaction	2017-02-16	
f)		n/a	
a) b)	Details of PDMR/person closely associa Name Position/status Initial notification/	Mr S A Hus President, G Pharmaceut	ssain Hobal icals
c)	amendment	Initial notifi	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor		•
	Name LEI	GlaxoSmith	Kline plc TVUYLO1D793
0)	Details of the transaction(s): section to b		
3.	instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each dat lucted	te; and (iv) each
a)	Description of the financial instrument	•	ares of 25 pence hary Shares')
b)	Nature of the transaction	to meet tax vesting of a 2014 under	009252882 Ordinary Shares liabilities for the wards granted in the Company's mance Share Volume(s)

£16.2437

27,371

n/a (single transaction)

- c) Price(s) and volume(s)
- d) Aggregated information

e) f)	Aggregated volume Price Date of the transaction Place of the transaction	2017-02-16 London Stock Exchange (XLON)
1.	Details of PDMR/person closely associa	ted with them ('PCA')
a)	Name	Mr B McNamara
b)	Position/status	CEO, Consumer Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each
		GlaxoSmithKline plc
a)	Description of the financial instrument	American Depositary Shares ('ADSs')
b)	Nature of the transaction	ISIN: US37733W1053 The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) \$40.57 10,082
	Aggregated information	n/a (single transaction)
d)		( 6
,	Aggregated volume Price	
e)	Date of the transaction	2017-02-16
f)	Place of the transaction	n/a
1.	Details of PDMR/person closely associa	
a) b)	Name Position/status	Mr D S Redfern Chief Strategy Officer
U)	Initial notification/	Chief Strategy Officer
c)	amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI Detaile of the transmission (c) and the transmission to be	5493000HZTVUYLO1D793
n	Details of the transaction(s): section to b	

- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

b)	Nature of the transaction	to meet tax li vesting of aw 2014 under th 2009 Perform Plan.	ordinary Shares abilities for the vards granted in ne Company's nance Share
c)	Price(s) and volume(s)	Price(s) £16.2437	Volume(s) 10,738
d)	Aggregated information	n/a (single tra	ansaction)
í	Aggregated volume Price Date of the transaction Place of the transaction	2017-02-16 London Stock (XLON)	k Exchange
1.	Details of PDMR/person closely associa		
	Name Position/status	Ms C Thoma SVP, Human	
c)	Initial notification/ amendment	Initial notific	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market partic	ipant, auction
	Name LEI	GlaxoSmithk 5493000HZT	Cline plc VUYLO1D793
	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	e repeated for (iii) each date ducted	(i) each type of
a)	Description of the financial instrument	each ('Ordinary Shares')	
b)	Nature of the transaction	to meet tax li vesting of aw 2014 under th 2009 Perform Plan.	ordinary Shares abilities for the vards granted in ne Company's nance Share
c)	Price(s) and volume(s)	Price(s) £16.2437	Volume(s) 15,320
d)	Aggregated information	n/a (single tra	
	Aggregated volume Price Date of the transaction Place of the transaction	2017-02-16 London Stock (XLON)	k Exchange

<sup>1.</sup> Details of PDMR/person closely associated with them ('PCA')

	0 0		
a)	Name	Mr P C Thomson	
b)	Position/status	SVP, Communications & Government Affairs	
c)	Initial notification/	Initial notification	
-	amendment Details of the issuer, emission allowance market participant, auction		
2.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of nstrument; (ii) each type of transaction; (iii) each date; and (iv) each lace where transaction(s) has been conducted		
		Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
b)	Nature of the transaction	ISIN: GB0009252882 The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.2437 7,307	
	Aggregated information	£16.2437 7,307	
d)	Aggregated information	n/a (single transaction)	
<b>u</b> )	Aggregated volume Price		
e)	Date of the transaction	2017-02-16	
f)	Place of the transaction	London Stock Exchange (XLON)	
1.	Details of PDMR/person closely associa	ted with them ('PCA')	
a)	Name	Mr D E Troy	
b)	Position/status	SVP & General Counsel	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance	e market participant, auction	
	platform, auctioneer or auction monitor	Class Gratth VI's and	
	Name	GlaxoSmithKline plc	
0)	LEI Details of the transaction(s): section to b	5493000HZTVUYLO1D793	
3	instrument; (ii) each type of transaction;		
5.	place where transaction(s) has been cond		
	r	GlaxoSmithKline plc	
		American Depositary Shares	
a)	Description of the financial instrument		
b)	Nature of the transaction	ISIN: US37733W1053 The withholding of ADSs to meet tax liabilities further to the vesting of awards granted	

		in 2014 unde 2009 Perforr Plan.	er the Company's nance Share
c)	Price(s) and volume(s)		Volume(s) 13,035
d)	Aggregated information	n/a (single tr	ansaction)
í	Aggregated volume Price Date of the transaction	2017-02-16	
c) f)	Place of the transaction	n/a	
1.	Details of PDMR/person closely associat	ed with them	('PCA')
	Name	Dr P J T Val	
b)	Position/status	President, Ro	&D
c)	Initial notification/ amendment	Initial notific	cation
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market partie	cipant, auction
	Name	GlaxoSmithl	·
b)	LEI		FVUYLO1D793
2	Details of the transaction(s): section to be instrument; (ii) each type of transaction;	-	• •
5.	place where transaction(s) has been cond		, and (IV) cach
			tres of 25 pence
a)	Description of the financial instrument	each ('Ordina	-
		ISIN: GB000	09252882
		The sale of C	Ordinary Shares
			iabilities for the
b)	Nature of the transaction	-	vards granted in
		2014 under the Company's 2009 Performance Share	
		Plan.	nance share
- )		Price(s)	Volume(s)
C)	Price(s) and volume(s)	£16.2437	32,996
	Aggregated information	n/a (single tr	ansaction)
d)			
	Aggregated volume Price Date of the transaction	2017-02-16	
e)	Place of the transaction	London Stoc	k Exchange
f)		(XLON)	A Lixenunge
1.	Details of PDMR/person closely associat	ed with them	('PCA')
	Name	Mrs V A Wł	
b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notific	cation
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market partie	cipant, auction
a)	1.	GlaxoSmithl	Kline plc

	6 6	•		
b)	LEI Details of the transaction(s): section to b		TVUYLO1D793 r (i) each type of	
3.	instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each lucted		
a)	Description of the financial instrument	Ordinary sha each ('Ordin	ares of 25 pence ary Shares')	
b)	Nature of the transaction	ISIN: GB0009252882 The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.		
c)	Price(s) and volume(s)	Price(s) £16.2437	Volume(s) 2,197	
d)	Aggregated information	n/a (single t	ransaction)	
	Aggregated volume Price			
e)	Date of the transaction	2017-02-16		
f)	Place of the transaction	London Stock Exchange (XLON)		
1.	Details of PDMR/person closely associa	ted with then	n ('PCA')	
a)	Name	Dr K Slaoui		
b)	Position/status	PCA of Dr M		
-)	Initial notification/	(Chairman,	Global Vaccines)	
c)	amendment	Initial notifi	cation	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market parti	cipant, auction	
	Name	GlaxoSmith	-	
b)		5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been conc	(iii) each dat lucted	e; and (iv) each	
		GlaxoSmith American D	Kline plc epositary Shares	
a)	Description of the financial instrument	('ADSs')		
b)	Nature of the transaction	meet tax lial the vesting of in 2014 und	733W1053 ding of ADSs to bilities further to of awards granted er the Company's mance Share	
c)	Price(s) and volume(s)	Price(s)	Volume(s) 249	
d)	Aggregated information	\$40.57 n/a (single t		
/		、 <i>6</i>	/	

Aggregated volume Price

e) Date of the transaction

2017-02-16

f) Place of the transaction n/a

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: February 20, 2017

By: VICTORIA WHYTE-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc